Vir Biotechnology (VIR) Return on Invested Capital (2019 - 2025)

Vir Biotechnology (VIR) reported Return on Invested Capital of 0.19% for Q4 2025, down 14.86% sequentially from 0.16% in Q3 2025.

Vir Biotechnology (VIR) Return on Invested Capital (2019 - 2025) Analysis & Trends

Vir Biotechnology (VIR) has 5 years of Return on Invested Capital data on file, last reported at 0.19% in Q4 2025.

For the quarter ending Q4 2025, Return on Invested Capital changed N/A year-over-year to 0.19%; the trailing twelve-month figure through Dec 2025 stood at 0.19% (changed N/A YoY), and the FY2020 full-year result was 0.32%, changed N/A from the prior year.
Return on Invested Capital slipped to 0.19% in Q4 2025, from 0.16% in the prior quarter.
In the past five years, Return on Invested Capital ranged from a high of 0.13% in Q2 2022 to a low of 0.26% in Q1 2025.
A 3-year average of 0.07% and a median of 0.06% in 2021 frame the typical range for Return on Invested Capital.
Across the five-year window, Return on Invested Capital advanced 3 bps in 2021 and advanced 18 bps in 2022, its largest moves.
Tracing VIR's Return on Invested Capital over 3 years: stood at 0.03% in 2021, then soared by 295 bps to 0.13% in 2022, then tumbled by 246 bps to 0.19% in 2025.
Business Quant data shows VIR's Return on Invested Capital at 0.19% in Q4 2025, 0.16% in Q3 2025, and 0.18% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.04%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Vir Biotechnology	1.38 Bn	1.38 Bn	-	-

Download Data